-
We are pleased to release our latest insight on addressing opioid analgesic use in workers' comp and auto no-fault. Inside you will find statistical trends impacting opioid analgesics today and our perspective on opioid analgesic use.
-
The U.S. Food and Drug Administration (FDA) announced that Camber Pharmaceuticals, Inc., voluntarily recalled one lot of montelukast sodium 10 mg tablets. This recall was issued following a discovery that sealed 30-count bottles, labeled as montelukast sodium 10 mg, from Camber were found to instead contain ninety tablets of losartan potassium 50 mg.
-
On August 16, 2018 the U.S. Food and Drug Administration (FDA) approved Teva’s generic versions of EpiPen and EpiPen Jr (epinephrine) auto-injectors for use in adults and pediatric patients weighing more than thirty-three pounds.
-
The patent for Lyrica® (pregabalin) was originally expected to expire at the end of 2018, making way for generic pregabalin to become available to consumers. But recent developments indicate that the patent may be extended
-
Pfizer announced that their July 1 medication price increases were rolled back due to market pressures. The intended price increases are not permanently suspended and Pfizer has stated that they have only been deferred until the end of the year.
-
The Missouri Legislature, in the waning hours of its session, passed legislation containing numerous changes to existing laws governing medical and pharmacy practices. One tucked away segment of the bill imposes prescribing restrictions for initial prescriptions of opioids to treat acute pain.
-
In a step to combat the opioid epidemic, the United States Department of Justice (DOJ) recently announced final adoption and publication of a new rule related to drug diversion and opioid production limits.